ID   LIM1899
AC   CVCL_4435
SY   Lim1899; LIM 1899; LIM-1899
DR   BioSample; SAMN07624414
DR   cancercelllines; CVCL_4435
DR   CBA; CBA-0163
DR   ColonAtlas; LIM1899
DR   Cosmic; 1238052
DR   Cosmic; 1482517
DR   Cosmic; 1486136
DR   Cosmic; 1805259
DR   Cosmic; 2301992
DR   ECACC; 12062001
DR   GEO; GSM1346879
DR   GEO; GSM1448136
DR   GEO; GSM3145716
DR   PRIDE; PXD000120
DR   Wikidata; Q54902528
RX   PubMed=1427983;
RX   PubMed=2386931;
RX   PubMed=12068308;
RX   PubMed=19378335;
RX   PubMed=23458625;
RX   PubMed=24295106;
RX   PubMed=24755471;
RX   PubMed=25926053;
CC   From: Ludwig Institute for Cancer Research, Melbourne Branch; Melbourne; Australia.
CC   Doubling time: 48 hours (PubMed=1427983).
CC   Microsatellite instability: Stable (MSS) (PubMed=19378335).
CC   Microsatellite instability: Instable (MSI) (PubMed=24755471; PubMed=25926053).
CC   Sequence variation: Mutation; HGNC; HGNC:2514; CTNNB1; Simple; p.Ser45Pro (c.133T>C); ClinVar=VCV000017589; Zygosity=Unspecified (PubMed=24755471).
CC   Sequence variation: Mutation; HGNC; HGNC:6407; KRAS; Simple; p.Gly12Ala (c.35G>C); ClinVar=VCV000045122; Zygosity=Heterozygous (PubMed=12068308; PubMed=19378335; PubMed=24755471).
CC   Omics: Glycomics; N-glycan profiling.
CC   Omics: Proteomics.
CC   Omics: Transcriptomics; Microarray.
CC   Omics: Transcriptomics; RNAseq.
CC   Derived from site: In situ; Colon; UBERON=UBERON_0001155.
ST   Source(s): CBA=CBA-0163; PubMed=25926053
ST   Amelogenin: X,Y
ST   CSF1PO: 10 (PubMed=25926053)
ST   CSF1PO: 10,11 (CBA=CBA-0163)
ST   D13S317: 9,12
ST   D16S539: 11 (PubMed=25926053)
ST   D16S539: 11,12 (CBA=CBA-0163)
ST   D18S51: 12
ST   D19S433: 13,14
ST   D21S11: 29 (PubMed=25926053)
ST   D21S11: 29,30 (CBA=CBA-0163)
ST   D2S1338: 20,24
ST   D3S1358: 13,15,16
ST   D5S818: 11,12,14 (CBA=CBA-0163)
ST   D5S818: 11,14 (PubMed=25926053)
ST   D7S820: 8,9
ST   D8S1179: 10,11
ST   FGA: 19,20,22
ST   TH01: 6,9.3
ST   TPOX: 9,11
ST   vWA: 17,20
DI   NCIt; C4349; Colon adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 10-04-25; Version: 32
//
RX   PubMed=1427983; DOI=10.1038/icb.1992.30;
RA   Whitehead R.H., Zhang H.H., Hayward I.P.;
RT   "Retention of tissue-specific phenotype in a panel of colon carcinoma
RT   cell lines: relationship to clinical correlates.";
RL   Immunol. Cell Biol. 70:227-236(1992).
//
RX   PubMed=2386931;
RA   Andrew S.M., Teh J.G., Johnstone R.W., Russell S.M., Whitehead R.H.,
RA   McKenzie I.F.C., Pietersz G.A.;
RT   "Tumor localization by combinations of monoclonal antibodies in a new
RT   human colon carcinoma cell line (LIM1899).";
RL   Cancer Res. 50:5225-5230(1990).
//
RX   PubMed=12068308; DOI=10.1038/nature00766;
RA   Davies H.R., Bignell G.R., Cox C., Stephens P.J., Edkins S., Clegg S.,
RA   Teague J.W., Woffendin H., Garnett M.J., Bottomley W., Davis N.,
RA   Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J.,
RA   Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S.,
RA   Hooper S., Wilson R., Jayatilake H., Gusterson B.A., Cooper C.S.,
RA   Shipley J.M., Hargrave D., Pritchard-Jones K., Maitland N.J.,
RA   Chenevix-Trench G., Riggins G.J., Bigner D.D., Palmieri G., Cossu A.,
RA   Flanagan A.M., Nicholson A., Ho J.W.C., Leung S.Y., Yuen S.T.,
RA   Weber B.L., Seigler H.F., Darrow T.L., Paterson H.F., Marais R.,
RA   Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.;
RT   "Mutations of the BRAF gene in human cancer.";
RL   Nature 417:949-954(2002).
//
RX   PubMed=19378335; DOI=10.1002/ijc.24289;
RA   Zhang H.-H., Walker F.E., Kiflemariam S., Whitehead R.H., Williams D.,
RA   Phillips W.A., Mikeska T., Dobrovic A., Burgess A.W.;
RT   "Selective inhibition of proliferation in colorectal carcinoma cell
RT   lines expressing mutant APC or activated B-Raf.";
RL   Int. J. Cancer 125:297-307(2009).
//
RX   PubMed=23458625; DOI=10.1021/pr3010869;
RA   Fanayan S., Smith J.T., Lee L.Y., Yan F.-F., Snyder M.P., Hancock W.S.,
RA   Nice E.;
RT   "Proteogenomic analysis of human colon carcinoma cell lines LIM1215,
RT   LIM1899, and LIM2405.";
RL   J. Proteome Res. 12:1732-1742(2013).
//
RX   PubMed=24295106; DOI=10.1021/pr400861m;
RA   Sethi M.K., Thaysen-Andersen M., Smith J.T., Baker M.S., Packer N.H.,
RA   Hancock W.S., Fanayan S.;
RT   "Comparative N-glycan profiling of colorectal cancer cell lines
RT   reveals unique bisecting GlcNAc and alpha-2,3-linked sialic acid
RT   determinants are associated with membrane proteins of the more
RT   metastatic/aggressive cell lines.";
RL   J. Proteome Res. 13:277-288(2014).
//
RX   PubMed=24755471; DOI=10.1158/0008-5472.CAN-14-0013;
RA   Mouradov D., Sloggett C., Jorissen R.N., Love C.G., Li S.,
RA   Burgess A.W., Arango D., Strausberg R.L., Buchanan D., Wormald S.,
RA   O'Connor L., Wilding J.L., Bicknell D.C., Tomlinson I.P.M., Bodmer W.F.,
RA   Mariadason J.M., Sieber O.M.;
RT   "Colorectal cancer cell lines are representative models of the main
RT   molecular subtypes of primary cancer.";
RL   Cancer Res. 74:3238-3247(2014).
//
RX   PubMed=25926053; DOI=10.1038/ncomms8002;
RA   Medico E., Russo M., Picco G., Cancelliere C., Valtorta E., Corti G.,
RA   Buscarino M., Isella C., Lamba S., Martinoglio B., Veronese S.,
RA   Siena S., Sartore-Bianchi A., Beccuti M., Mottolese M.,
RA   Linnebacher M., Cordero F., Di Nicolantonio F., Bardelli A.;
RT   "The molecular landscape of colorectal cancer cell lines unveils
RT   clinically actionable kinase targets.";
RL   Nat. Commun. 6:7002.1-7002.10(2015).
//